Novel Combination Product with Activity Against MRSA, MDR-Enterics and Pseudomonas

DESCRIPTION provided by applicant This year Phase I SBIR Application centers on completing the lead optimization of an andquot ultra broad spectrumandquot carbapenem UBSC lead series with an unprecedented antibacterial spectrum of activity including MRSA Enterobacteriaceae and Pseudomonas aeruginosa At the completion of lead optimization the resulting Preclinical Development Candidate will be paired with a proprietary in house lactamase inhibitor BLI to protect against resistance by Ambler Class A B and D carbapenemase producing Gram negatives Further advancement through IND enabling preclinical studies will be proposed in the Phase II SBIR stage Ultimately it is envisioned that this new combination product will provide a unique clinical option for empiric therapy of multi drug resistant polymicrobial infections in the hospital general ward and ICU and as a second line therapy for susceptible organisms PUBLIC HEALTH RELEVANCE We are optimizing to st Preclinical Candidate a class of ultra broad spectrum carbapenems with activity that extends to MRSA Enterobacteriaceae and Pseudomonas aeruginosa The compounds are being paired with a proprietary lactamase inhibitor with activity that extends to all Ambler classes of carbapenemases The combination would represent a powerful new single treatment option against problematic multi drug resistant pathogens